Eli Lilly's next Phase III trial is assessing whether lepodisiran can not only reduce levels of lipoprotein(a) but also ...

Patients at risk for heart disease experienced significant reductions in apolipoprotein B and LDL cholesterol levels on ...

Clinical Trial Growth & Future Outlook: Analysis of the 150+ industry-sponsored siRNA clinical trials conducted between 2020 and 2024, with a 79.5% CAGR reflecting significant industry investment.

Researchers used siRNA to temporarily inhibit an essential ... where the sequencing and bioinformatics analysis were crucial in ensuring the precision of the gene edits. "We had to develop new ...

This report provides insights for biotech and pharmaceutical companies leveraging RNA-based precision medicine to ... Unlocking the Potential of siRNA for Drug Development siRNA therapeutics ...

Reporting in Nature, Kumar and colleagues have now developed a method to target small-interfering RNA (siRNA) to the CNS, providing a safe and non-invasive approach for the delivery of this new ...

The company's portfolio advances therapies for age-related diseases, with an initial focus on siRNA payloads ... aims to develop next-generation precision therapies using novel protein design ...